Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A preparation method of composition for treating osteoarthritis

A technology for osteoarthritis and composition, which is applied in the field of composition, can solve the problem that the physiological state of cells cannot be fully realized, and achieve the effect of surface attachment, simple manufacturing process, and promotion of survival

Active Publication Date: 2018-12-11
天晴干细胞股份有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, all these methods are carried out under the condition of the cell body outside, and the cell suspension is not deoxygenated when it is imported. When the cells are injected into the body, due to the complex inflammation and nutritional environment, the physiological state of the cells will be changed. Fully realize the experimental results obtained in vitro

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A preparation method of composition for treating osteoarthritis
  • A preparation method of composition for treating osteoarthritis
  • A preparation method of composition for treating osteoarthritis

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0027] Specific embodiment 1: The active ingredients of the composition for treating osteoarthritis of this embodiment include mesenchymal stem cells and cytokines, and the concentration of mesenchymal stem cells of the composition is 5×10 5 ~5×10 7 A / mL, the cytokine is prepared from FGF2-rich plasma and VEGF-rich plasma in a volume ratio of 1:3-10.

[0028] The mesenchymal stem cells may be bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, umbilical cord mesenchymal stem cells, umbilical cord blood mesenchymal stem cells, amniotic membrane mesenchymal stem cells, placental mesenchymal stem cells, or endometrial origin Of mesenchymal stem cells.

[0029] The cytokine-rich plasma can regulate the arthritic microenvironment and reduce pain, and at the same time provide nutrition for the survival of co-transplanted mesenchymal stem cells, promote their effective colonization and survival in the body, and prolong the regeneration and microenvironment of stem cells in ...

specific Embodiment approach 2

[0030] Specific embodiment two: this embodiment is different from specific embodiment one in that the FGF2 concentration in the FGF2-rich plasma is 40-80 pg / mL. Others are the same as the first embodiment.

specific Embodiment approach 3

[0031] Specific embodiment three: This embodiment is different from specific embodiment one or two in that the VEGF concentration in the VEGF-rich plasma is 150-350 pg / mL. Others are the same as the first or second embodiment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a composition for treating osteoarthritis as well as a preparation method and an application of the composition, relates to a composition as well as a preparation method and an application thereof, and provides a composition for treating osteoarthritis and a preparation method and an application of the composition. The composition comprises the following effective components: mesenchymal stem cells and cytokine; and the cytokine is prepared from FGF2-rich plasma and VEGF-rich plasma. The method comprises the following steps: 1, preparing platelet-rich plasma; 2, preparing FGF2 factor-rich plasma; 3, preparing VEGF factor-rich plasma; and 4, mixing the FGF2 factor-rich plasma with the VEGF factor-rich plasma, balancing the mixed plasma under the oxygen partial pressure of 25-60mmHg, and adding the mesenchymal stem cells to obtain the composition for treating osteoarthritis. In the preparation process of the composition, an oxygen supply environment which is similar to the oxygen partial pressure in a human joint is adopted; the adaptive capacity of stem cells is promoted; and the composition plays a relatively good role in repairing osteoarthritis, and is used for preparing medicines for treating osteoarthritis.

Description

Technical field [0001] The invention relates to a composition, its preparation method and its application. Background technique [0002] Osteoarthritis (OA) is a common, multiple, and degenerative disease in the elderly. Its typical pathological features are destruction of articular cartilage, changes in subchondral bone structure, and the occurrence of osteophytes. At present, 55% of people over 60 years old in my country suffer from osteoarthritis, and the prevalence rate increases year by year with the increase of age. As China gradually enters an aging society and the average life expectancy of Chinese people has increased, about 120 million people are now suffering from osteoarthritis. Due to local poor blood supply and autologous bone marrow stem cell disease, patients with osteoarthritis usually have limited self-regeneration and repair capabilities. Without therapeutic intervention, joint repair and functional recovery cannot be achieved. Drug treatment and surgery can ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K35/28A61P19/02A61K35/16
CPCA61K35/16A61K35/28A61K38/1825A61K38/1866A61K2300/00
Inventor 张怡芦慧颖刘艳青
Owner 天晴干细胞股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products